Therapy News and Research

RSS

Group therapy helps improve healthy behavior in people with cardiovascular risk factors

Peer group support, in the form of group therapy, was found to help improve healthy behavior in people with cardiovascular risk factors, according to a study released today by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital. Mount Sinai Heart is ranked No. 7 in the nation by U.S. News & World Report in its 2015 "Best Hospitals" issue.

10 Nov 2015

HSS researchers help identify lupus patients at increased risk of problem pregnancies

For years doctors have been advising patients with lupus not to get pregnant. It was assumed that the likelihood of pregnancy complications was too high in this population. However, ongoing work by researchers at Hospital for Special Surgery is helping identify those lupus patients who are - and aren't - at increased risk of problem pregnancies.

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

Innovative high school health program helps students maintain healthier weights, alleviate depression

An innovative high school health program helped students maintain healthier weights and even alleviated severe depression for a full year after the program ended.

10 Nov 2015

Brief manualized treatment helps people with problematic caffeine use lower caffeine consumption

Engaging in brief, cognitive-behavioral therapy is an effective treatment for helping people with problematic caffeine use lower their caffeine consumption, according to a new study coauthored by Laura M. Juliano, Ph.D., a professor of psychology at American University.

10 Nov 2015

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

HIFU Prostate Services announces groundbreaking partnerships to offer prostate cancer treatments

HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatment using High Intensity Focused Ultrasound ("HIFU"), announces groundbreaking partnerships with Michael J. Lazar, MD in Santa Rosa, Calif. and John H. Jurige, MD in Louisville, Ky., to offer HIFU treatments for prostate cancer.

9 Nov 2015

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms.

9 Nov 2015

Arthritis patients to be greater contributors to clinical guideline development

CreakyJoints®, the online, non-profit, arthritis patient support community with more than 80,000 members, today announced the publication of “When patients write the guidelines: Patient panel recommendations for the treatment of rheumatoid arthritis,” in Arthritis Care & Research (AC&R), an official journal of the American College of Rheumatology (ACR).

9 Nov 2015

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

NTU Singapore scientists harness dead bacteria to destroy colon tumours cells effectively

Scientists from Nanyang Technological University have successfully used dead bacteria to kill colorectal cancer cells. Harvesting the Clostridium sporogenes bacteria found commonly in soil, the NTU team was able to harness the bacteria in its dead form, and its secretions, to destroy colon tumours cells effectively.

9 Nov 2015

CareFusion to display new respiratory solutions at AARC Congress

CareFusion, a BD company, will be displaying new respiratory solutions that are designed to put patients first, whether ventilated or breathing on their own, at the American Association for Respiratory Care Congress being held Nov. 7-10 in Tampa, Fla.

6 Nov 2015

MPP announces expansion of mandate to hepatitis C and TB medicines

The Medicines Patent Pool, the world's only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP's proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis.

6 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Therapy News and Research

Group therapy helps improve healthy behavior in people with cardiovascular risk factors

HSS researchers help identify lupus patients at increased risk of problem pregnancies

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Innovative high school health program helps students maintain healthier weights, alleviate depression

Brief manualized treatment helps people with problematic caffeine use lower caffeine consumption

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Astellas enters into definitive agreement to acquire Ocata

New funding for Centenary's life saving research

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

HIFU Prostate Services announces groundbreaking partnerships to offer prostate cancer treatments

Nightstar announces $35 million Series B financing round

Arthritis patients to be greater contributors to clinical guideline development

Diabetes drug liraglutide ineffective in patients with advanced heart failure

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

NTU Singapore scientists harness dead bacteria to destroy colon tumours cells effectively

CareFusion to display new respiratory solutions at AARC Congress

MPP announces expansion of mandate to hepatitis C and TB medicines

Viralytics enters into clinical trial collaboration agreement with MSD

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News